Williams Jones & Associates’s CASI Pharmaceuticals CASI Stock Holding History

Williams Jones & Associates’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,781	Closed	-$20K	–	412
2016 Q4	$20K	Hold	1,781	–	–	﹤0.01%	376
2016 Q3	$20K	Hold	1,781	–	–	﹤0.01%	396
2016 Q2	$21K	Buy	1,781 +172	+11%	+$2.17K	﹤0.01%	389
2016 Q1	$17K	Hold	1,609	–	–	﹤0.01%	355
2015 Q4	$15K	Hold	1,609	–	–	﹤0.01%	347
2015 Q3	$17K	Hold	1,609	–	–	﹤0.01%	357
2015 Q2	$29K	Hold	1,609	–	–	﹤0.01%	373
2015 Q1	$24K	Hold	1,609	–	–	﹤0.01%	374
2014 Q4	$21K	Buy	+1,609	New	+$25.2K	﹤0.01%	374
2014 Q2	–	Sell	-4,250	Closed	-$77K	–	367
2014 Q1	$77K	Buy	+4,250	New	+$80.4K	﹤0.01%	351
2013 Q3	–	Sell	-2,125	Closed	-$43K	–	363
2013 Q2	$43K	Buy	+2,125	New	+$41.2K	﹤0.01%	335

Other funds holding CASI

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Williams Jones & Associates's CASI Position: Q1 2017 in Review

Williams Jones & Associates sold out of CASI Pharmaceuticals (CASI) in Q1 2017, closing a stake of 1,781 shares — an estimated $20K sold.

Williams Jones & Associates first reported a position in CASI in Q2 2013 and held it in 11 quarters. The position peaked at $77K in Q1 2014. 25 funds tracked by Wall St. Rank hold CASI as of Q1 2017.

Williams Jones & Associates reported no remaining CASI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Williams Jones & Associates sold 1,781 CASI Pharmaceuticals shares in Q1 2017, an estimated $20K.
Williams Jones & Associates first reported a position in CASI Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Williams Jones & Associates's CASI Pharmaceuticals position peaked at $77K in Q1 2014.
25 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2017.

Based on Williams Jones & Associates's 13F filing for Q1 2017, filed 15 May 2017.